Corneal Collagen Crosslinking for Progressive Keratoconus & Ectasia Using

Status Active, not recruiting

Clinical Trial Summary

Corneal collagen crosslinking (CXL) has been proposed as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. During the CXL procedure, the central corneal thickness has been shown to significantly change. The investigator's believe that better maintenance of corneal thickness potentially could have benefits of better reproducibility of the crosslinking effect with improved predictability of results.

Clinical Trial Description

The objective of this study is to investigate the difference between the two riboflavin preparations during UV (ultraviolet) administration. Both riboflavin preparations currently are in general use worldwide and in U.S. clinical trials of corneal collagen crosslinking. The first preparation contains riboflavin in a dextran solution, which may tend to dehydrate the cornea and keep it thinner. The second preparation contains riboflavin in a solution without dextran; in this case, the relative hypotonicity may tend to keep the cornea better hydrated and thicker. The primary goal of the study is to see if the use of hypotonic riboflavin (rather than riboflavin with dextran) better maintains consistent corneal thickness during the CXL procedure. The second goal of the study is to determine if better maintenance of corneal thickness potentially could have benefits of better consistency of the procedure, decrease in corneal haze formation, and improved safety of the endothelial cells. Safety and efficacy outcomes will then be compared between the groups. In particular, we will compare the corneal thickness measured by ultrasonic pachymetry immediately after the CXL procedure in the randomized eyes. Secondary outcomes will include visual acuity, longer term corneal thickness changes, and corneal steepness changes. Safety assessments will include a tabulation of adverse events, patient symptoms, loss of visual acuity, changes in endothelial cell density, slit lamp examination of the cornea and lens, and contact lens tolerance for contact lens wearers ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01152541
Study type	Interventional
Source	Cornea and Laser Eye Institute
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	June 2010
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04570020` - Scleral Lens Fitting Using Wide-Field OCT
Recruiting	`NCT02921009` - McNeel Eye Center Corneal Crosslinking Study	N/A
Terminated	`NCT02762253` - Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.	Phase 2
Completed	`NCT01691651` - Botulinum Toxin A for the Treatment of Keratoconus	N/A
Completed	`NCT01527708` - Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas	N/A
Completed	`NCT01527721` - Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus	N/A
Recruiting	`NCT00841386` - Treatment of Keratoconus Using Collagen Cross-Linking	Phase 2/Phase 3
Completed	`NCT00347074` - A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients	N/A
Completed	`NCT03187912` - Accelerated Corneal Cross-linking With Different Riboflavin Solutions	Phase 3
Completed	`NCT00584285` - Corneal Topographer Fluorescein Patterns
Completed	`NCT03511495` - Reliability of Topography Measurements in Keratoconus
Not yet recruiting	`NCT05395650` - Cyanocobalamin as Photosensitizing Agent
Completed	`NCT04418999` - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus	Early Phase 1
Completed	`NCT05019768` - Topo-pachimetric Accelerated Epi-On Cross-linking Compared to Dresden Protocol Using Riboflavin With Vitamin E TPGS	N/A
Completed	`NCT03235856` - Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE
Withdrawn	`NCT01789333` - Higher Irradiance in Keratoconus Ectasia	N/A
Completed	`NCT05114928` - Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.
Completed	`NCT03647046` - Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus	N/A
Recruiting	`NCT04439552` - fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
Recruiting	`NCT06100939` - Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms